Clinical trials: Chiari Malformation Type 2
Actinic Keratosis
Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2
Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.
- Trial name
- NCT00659893
- Testing
- PEP005 Topical gel
- Where
- 13 sites in United States, Australia
- Volunteers
- 64 people
- Sponsor
- Peplin
Actinic Keratoses
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
The purpose of this study is to determine the extent of systemic absorption of PEP005 when applied topically for the treatment of actinic keratoses.
- Trial name
- NCT00544258
- Testing
- PEP005
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Peplin
Headache Migraine Chronic
A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine.
- Trial name
- NCT06167655
- Testing
- Neurostimulator
- Where
- 23 sites in United States, Australia
- Volunteers
- 250 people
- Sponsor
- ShiraTronics
Actinic Keratosis
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once…
- Trial name
- NCT01922050
- Testing
- LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X
- Where
- 25 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp
The purpose of this study is to prove the safety and efficacy of Levulan Kerastick (aminolevulinic acid HCl) for Topical Solution 20% followed by 10 J/cm2 of blue light delivered at 10 mW/cm2 or 20 mW/cm2 in the treatment of…
- Trial name
- NCT03024060
- Testing
- ALA, Vehicle, IBL 20 mW
- Where
- 7 sites in United States
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
- Trial name
- NCT02361216
- Testing
- Ingenol Mebutate, Vehicle
- Where
- United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or…
- Trial name
- NCT01820260
- Testing
- Ingenol mebutate gel
- Where
- United States
- Volunteers
- 395 people
- Sponsor
- LEO Pharma
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Actinic Keratosis
Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions
This is an open-label, uncontrolled, non-randomised multi-centre trial in which 3 parallel groups will be enrolled. The trial includes three active treatment groups.
- Trial name
- NCT02124239
- Testing
- Ingenol mebutate
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- LEO Pharma
Actinic Keratoses
A Study to Determine the Optimal Tolerated Regime and Safety of PEP005 Topical Gel
The purpose of this study is to determine the optimal tolerated regime of PEP005 for the treatment of actinic keratoses of the face or face and scalp.
- Trial name
- NCT00427050
- Testing
- PEP005
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 50 people
- Sponsor
- Peplin
Actinic Keratoses
Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis
This Phase I study is designed to evaluate the systemic exposure and safety of KX2-391 Ointment in adult subjects when applied to an area of skin containing at least 5 clinically typical, visible, and discrete Actinic Keratosis…
- Trial name
- NCT03575780
- Testing
- KX2-391 Ointment 1%
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Athenex, Inc.
Alzheimer's Disease
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24).
- Trial name
- NCT00428389
- Testing
- Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
- Where
- 23 sites in United States
- Volunteers
- 262 people
- Sponsor
- Novartis
Hypogonadism
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.
- Trial name
- NCT01323140
- Testing
- testosterone matrix transdermal system
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Watson Pharmaceuticals
Venous Leg Ulcers
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S.
- Trial name
- NCT01737762
- Testing
- HP802-247, Vehicle
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Healthpoint
Keratosis
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands.
- Trial name
- NCT00116649
- Testing
- imiquimod cream
- Where
- 32 sites in United States
- Volunteers
- 551 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Healthy
Study to Evaluate the Pharmacokinetics (PK), Safety, Tolerability of Single-Dose Transdermal Rotigotine in Japanese and Caucasian Healthy Male / Female Subjects
To investigate the Pharmacokinetics (PK) of transdermally delivered Rotigotine in Japanese and Caucasian Female and Male Healthy Subjects.
- Trial name
- NCT01761526
- Testing
- Rotigotine transdermal patch
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- UCB BIOSCIENCES GmbH
Parkinson's Disease
Trial to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine in Healthy Korean Subjects
The objective of this trial is to investigate the PK (Pharmacokinetic) of repeated-dose applications of the Rotigotine transdermal patch in healthy young male and female Korean subjects to be submitted to MFDS for new drug…
- Trial name
- NCT01964573
- Testing
- Rotigotine
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2 trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily treatment for 2, 3 or 4 consecutive days…
- Trial name
- NCT01998984
- Testing
- ingenol mebutate
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- LEO Pharma
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive…
- Trial name
- NCT02120456
- Testing
- LEO 43204
- Where
- 21 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- LEO Pharma